TNFSF13B and metabolic dysfunction-associated steatohepatitis: Considering the pro-inflammatory properties of B cells in NASH pathogenesis and the association between BAFF levels and the severity of steatohepatitis and fibrosis, targeting B cells may prove to be an effective strategy in reducing liver inflammation and fibrosis.